Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Nov 24;22(7):1687–1698. doi: 10.1158/1078-0432.CCR-14-3378

Figure 6. TH-302 administration after chemotherapy improves survival in a syngeneic AML murine model.

Figure 6

C57Bl/6 mice were injected with AML1/ETO-GFP cells and treated with doxorubicin and cytarabine (DA). A. Percentage of circulating GFP-positive cells at the end of chemotherapy. B. Pimonidazole (PIMO) immunostaining reveals persistence of hypoxia in the leukemic BM post-chemotherapy. Shown are PIMO and hematoxylin and eosin (H&E) staining of BM from control (PBS) and treated mice that were euthanized 1 week after completing the treatment and 3 h after receiving PIMO. C. Optical density images of C57Bl/6 mice transplanted with AML1/ETO-LUC-GFP cells and treated with vehicle (PBS) or chemotherapy for 5 days; after 1 week of recovery, mice were treated with TH-302. D. Survival curves of mice treated as described in C (N=6/group). * P<0.05; ** P<0.01; *** P<0.001.